



SCIENTIFIC LETTERS

Congenital adrenal hypoplasia and hypogonadotropic hypogonadism: Phenotypic variability of the DAX-1 gene R267P mutation[☆]

Hipoplasia adrenal congénita e hipogonadismo hipogonadotrópico: variabilidad fenotípica de la mutación R267P del gen DAX-1

Mutations in the DAX-1 gene (*DAX1*) (chromosome X gene 1 of dosage-sensitive sex reversal congenital adrenal hypoplasia; also called NROB1 gene [Nuclear receptor subfamily 0, group B, member 1] MIM ID *300473) are responsible for adrenal failure and hypogonadotropic hypogonadism in patients with congenital adrenal hypoplasia (OMIM# 300200). Mutations involve a loss of expression of the steroidogenic acute regulatory protein (StAR) and LH β mediated by repression of the steroidogenic factor (*17 α* -OH), as well as a decreased GnRH expression.¹ More than 100 mutations in *DAX1* have been reported to date.¹ This clinical condition should be ruled out in patients with salt-losing syndromes once common causes of adrenal failure, such as defects in steroidogenesis (*CYP21A2*) and metabolic changes (adrenoleukodystrophy), have been ruled out. We report the case of two brothers with the mutation (R267P) and genotypic–phenotypic heterogeneity.

Case 1

A 2-month-old male with vomiting and signs of dehydration and a poor weight curve for the previous 15 days. Laboratory tests showed hyponatremia and hyperkalemia, normal cortisol levels, and no elevation in steroidogenic precursors (Table 1). Primary hyperaldosteronism was diagnosed, and replacement therapy was started with mineralocorticoids and supplemental sodium chloride, with an adequate initial clinical and biochemical response. At 17 months of life, the patient was diagnosed with an associated glucocorticoid deficiency based on progressive hyperpigmentation, growth curve stability with weight at the 50th percentile (P) and P25 height, and low plasma cortisol levels. There

was no family history of autoimmune disease, abortions or stillbirths, or neurological disease, and the patient had no siblings at the time of diagnosis. Tests for anti-adrenal antibodies and very long chain fatty acids were negative. The growth curve was normal under treatment with glucocorticoids 10 mg/m² SC/day and mineralocorticoid 0.175 mg/day until progressive growth deceleration with delayed bone maturation started at 8 years. At 13 years and nine months, the patient showed no development of secondary sexual characteristics, a combined pituitary test with no growth hormone (GH) response to an insulin-induced hypoglycemia test (basal GH 0.5 ng/mL; maximum peak [mp] 1 ng/mL) and to a clonidine test with steroid impregnation (basal GH <0.2 ng/mL; mp 0.2 ng/mL); gonadotropin and androgen levels suggesting hypogonadotropic hypogonadism, with an abnormal HCG test (basal total testosterone 0.1 ng/mL; mp 1 ng/mL). Adrenal and hypothalamo–hypophyseal MRI was unremarkable. At 14 years, with a bone age of 10 years, treatment was started with testosterone propionate 50 mg/month (4 doses), with no growth increase. At 14 years and 7 months, when the patient had a height of 142.6 cm (<P3), a growth velocity of 2.6 cm/year, and a bone age of 10–11 years, treatment with recombinant growth hormone (rGH) was added. Growth velocity increased to 8 cm/year in the first year and subsequently decreased to 6.5–4.7 cm/year. At 20 years, the patient had a height of 170 cm (P25; target height 167 cm) and had adult secondary sexual characteristics. Treatment with rGH is currently continued for adult GH deficiency.

Case 2

A male diagnosed at 18 months with adrenal insufficiency due to salt-losing syndrome (Table 1). Two weeks before diagnosis, after receiving the oral DTP and polio vaccine, the patient showed a low mood and progressive anorexia, with abdominal pain at night and foul-smelling soft stools. Weight and height gain was adequate until 16–17 months of age, when a flat weight curve, weight <P3, height between P25 and P50, and hyperpigmentation were seen. An 8-year-old brother had been diagnosed with primary adrenal insufficiency (case 1). Tests for anti-adrenal antibodies and very long chain fatty acids were negative. The patient had a normal weight and height evolution under treatment with glucocorticoids at 10 mg/m² SC/day and mineralocorticoid at 0.125 mg/day, and received oral NaCl supplements in the first year following diagnosis. At 12 years, a gradual decrease in growth velocity was seen, as well as no

[☆] Please, cite this article as: Sánchez-Pacheco M, et al. Hipoplasia adrenal congénita e hipogonadismo hipogonadotrópico: variabilidad fenotípica de la mutación R267P del gen DAX-1. Endocrinol Nutr. 2012;59:140–2.

Table 1 Basal biochemical and hormone measurements during follow-up.

	Onset		Pubertal	Current
<i>Case 1</i>				
Na/K, mEq/L [135–150]/[3.5–5.5]	124/5.9	145/5.5	144/5.5	137/5
Cortisol, mg/dL [8–25]	14	1.7	1.1	
ACTH, pg/mL [9–40]	120	>360	128	3842
PRA, ng/mL/h [1.63–3.63]	>148		17.6	21
PA, pg/mL [38–313 pg/mL]	123		<16	<1
DHEA-S, ng/dL [0.7–3.9 ng/dL]	ND	1.4	<1	
17-OH-PG, ng/mL [0.7–3.6 ng/mL]	1,25			
LH, mIU/mL [1.5–10 mIU/mL]			<0.1	
TT, ng/mL [3–10 ng/mL]			<0.1	6.39
IGF-1, ng/mL [131–540 ng/mL]			800 ^a	339
GH, ng/mL			<0.2	
TSH, mIU/L [0.38–4.84 mIU/L]	ND		1.15	1.4
FT4, ng/dL [0.8–2 ng/dL]	ND		1.22	1.4
<i>Case 2</i>				
Na/K, mEq/L [135–150]/[3.5–5.5]	118/6			143/4.2
Cortisol, mg/dL [8–25]	1			<1
ACTH, pg/mL [9–40]	>1500			1832
PRA, ng/mL/h [1.63–3.63]				5.5
PA, pg/mL [38–313 pg/mL]	25			0.4
DHEA-S, ng/dL [0.7–3.9 ng/dL]	ND		ND	
17-OH-PG, ng/mL [0.7–3.6 ng/mL]	2			
LH, mIU/mL [1.5–10 mIU/mL]			0.4	
TT, ng/mL [3–10 ng/mL]			<0.08	0.47
IGF-1, ng/mL [131–540 ng/mL]			ND	460
GH, ng/mL			ND	
TSH, mIU/L [0.38–4.84 mIU/L]	ND		ND	5.39
FT4, ng/dL [0.8–2 ng/dL]	ND		ND	1.7

ACTH: adrenocorticotrophic hormone; PA: plasma aldosterone; PRA: plasma renin activity; DHEA-S: dehydroepiandrosterone sulphate; 17-OH-PG: progesterone; IGF-1: insulin-like growth factor; LH: luteinizing hormone; ND: no data available; FT4: free T4; TSH: thyroid-stimulating hormone; TT: total testosterone.

^a On treatment with recombinant GH.

progression of pubertal development. At 14 years, a combined pituitary test showed a somatotrophic axis with no changes and hypogonadotropic hypogonadism (basal and mp LH < 0.07 mIU/mL, basal and mp FSH 0.6/0.8 IU/L, basal total testosterone < 0.08 ng/mL). Testosterone propionate (50 mg/month) was started for pubertal induction, leading to increased growth and bone maturation and progressive development of secondary sexual characteristics. At 17 years of age, the patient had a height of 165.5 cm (P15) and a bone age of 14.5 years, with a persistent growth velocity of 6 cm/year.

A molecular study of both patients and their parents by direct *DAX1* sequencing using various pairs of primers for exon 1 amplification showed that both the index case (case 1) and his younger brother had in hemizygosia a change in position 800 (c.800G > C), which caused substitution at protein level p.Arg267Pro (NR0B1.0004, ARG267PRO). A DNA study of the mother confirmed the presence of the same mutation in heterozygosia. No mutation was found in the father.

Chromosome X-linked heredity is usually recessive for women. In the reported case, the mother had the mutation in heterozygosia and was therefore a carrier, because the normal dominant allele prevented the expression of the

affected gene. The XY sons had the mutation in hemizygosia and were therefore affected by the condition.

There is a phenotypic heterogeneity associated with *DAX1* mutations. The lack of genotype–phenotype correlation in some mutations is presumably caused by the influence of other modifying genes, which leads to significant within-family variations in age at onset and expression.² Onset usually occurs at an earlier age in the younger brother. Family history usually reveals the presence of unexplained deaths of children during infancy or siblings with congenital adrenal hypoplasia. The form of presentation is, in most cases, a salt-losing syndrome with hyponatremia, hyperkalemia, and metabolic acidosis in the first months of life, preceded by the loss of a channel of growth. Subjects may erroneously be diagnosed with *CYP21A2* deficiency, isolated hypoaldosteronism, or pseudohypoaldosteronism.² While basal cortisol at diagnosis may vary, ACTH is invariably elevated (case 1) and there is an inadequate cortisol elevation in response to the ACTH stimulation test. Aldosterone deficiency precedes hypocortisolism in most patients (case 1).³ There have been reports of cases of transient isosexual precocity in infancy and childhood with high testosterone levels for age, penile elongation, sometimes associated with testicu-

lar enlargement, and no other signs of sexual development; some mechanisms proposed for this phenomenon implicate the NROB1 gene in the prepubertal control mechanism of the gonadal axis, ACTH-mediated stimulus of testicular steroidogenesis, or autonomous hyperplasia of Leydig cells.² In the pubertal period, these patients will require testosterone replacement for the development of secondary sexual characteristics. Since *DAX1* abnormalities may affect testicular development and spermatogenesis, fertility treatment using pulsatile GnRH and gonadotropins is often ineffective.⁴ Mental disability (motor, speech, and social behavior) may also occur. To our knowledge, there are no cases reported in the literature of an association between *DAX1* and GH deficiency as seen in case 1.

DAX1 mutations account for 58% of cases of primary adrenal insufficiency of "unknown etiology" in children (newborn-13 years) in whom autoimmune causes, deficient steroidogenesis, or metabolic causes have been ruled out.⁵ Although it does not change the therapeutic strategy, molecular diagnosis allows for genetic counseling to relatives and is warranted in children with the onset of a salt-losing syndrome of unknown etiology, with or without associated cortisol deficiency. High clinical suspicion is required to prevent erroneous diagnosis and to allow for an adequate therapeutic approach.

References

1. Li N, Liu R, Zhang H, Yang J, Sun S, Zhang M, et al. Seven novel *DAX1* mutations with loss of function identified in Chinese patients with congenital adrenal hypoplasia. *J Clin Endocrinol Metab.* 2010 [Epub ahead of print].
2. Landau Z, Hanukoglu A, Sack J, Goldstein N, Weintrob N, Eliakim A, et al. Clinical and genetic heterogeneity of congenital adrenal hypoplasia due to *NROB1* gene mutations. *Clin Endocrinol (Oxf).* 2010;72:448-54.
3. Wiltshire E, Couper J, Rodda C, Jameson JL, Achermann JC. Variable presentation of X-linked adrenal hypoplasia congenita. *J Pediatr Endocrinol Metab.* 2001;14:1093-6.
4. Mantovani G, Ozisik G, Achermann JC, Romoli R, Borretta G, Persani L, et al. Hypogonadotropic hypogonadism as a presenting feature of late-onset X-linked adrenal hypoplasia congenita. *J Clin Endocrinol Metab.* 2002;87:44-8.
5. Lin L, Gu WX, Ozisik G, To WS, Owen CJ, Jameson JL, et al. Analysis of *DAX1* (*NROB1*) and steroidogenic factor-1 (*NR5A1*) in children and adults with primary adrenal failure: ten years' experience. *J Clin Endocrinol Metab.* 2006;91:3048-54.

Myriam Sánchez-Pacheco^{a,*}, Oscar Moreno-Pérez^a,
Ruth Sánchez-Ortiga^a, Antonio Picó^a, Francisca Moreno^b

^a *Sección de Endocrinología y Nutrición, Hospital General Universitario de Alicante, Alicante, Spain*

^b *Sección de Endocrinología Pediátrica, Hospital La Fe de Valencia, Valencia, Spain*

* Corresponding author.

E-mail address: myriam.sanchez-pacheco@hotmail.com
(M. Sánchez-Pacheco).

Thymic carcinoid in the setting of a multiple endocrine neoplasia syndrome (MEN 1). Prophylactic thymectomy?[☆]

Carcinoide tímico en el contexto de un síndrome de neoplasia endocrina múltiple (MEN 1). ¿Timectomía profiláctica?

The thymus gland is one of the most common sites of neuroendocrine tumors. Approximately 150 cases have been reported since 1972, of which 25% were associated with multiple endocrine neoplasia type 1 syndrome (MEN 1).¹ Thymic carcinoid has been reported in 2.6-5% of patients with MEN 1 in retrospective series.²

This type of tumor is more frequent in males, mostly smokers (>95%), and is usually non-functioning. It is the most common cause of anterior mediastinal masses in patients with MEN 1. The tumor is generally detected in advanced stages based on local symptoms or as a chance radiographic finding, and shows an aggressive behavior in most cases.

The most common cause of death in current MEN 1 is potential malignancy of gastroenteropancreatic neuroendocrine tumors,³ which are more frequent than thymic carcinoids. However, since the effectiveness of the treatment of these tumors has increased, some studies have suggested that it is the development of thymic or other carcinoids that limits survival in patients diagnosed with MEN 1. This is because they are much more aggressive, depending on their histology and local invasion.^{1,2,4}

The natural history, results of early diagnosis, survival, or most adequate treatment are still unknown.

We report the case of a 48-year-old male patient who underwent surgery through a trans-sphenoidal approach for pituitary macroprolactinoma at 25 years of age, and repeat surgery four years later through a left frontoparietal craniotomy followed by residual tumor radiotherapy. At 32 years of age, after suffering a perforated ulcer, he was diagnosed with multicentric pancreatic gastrinoma, and treatment was started with proton pump inhibitors and somatostatin analogs.

Primary hyperparathyroidism secondary to parathyroid hyperplasia was not detected until the age of 37. This is unusual, because this is usually the first sign in patients with MEN 1. Total parathyroidectomy was performed.

A genetic study in that same year revealed the presence of the Q450X familial mutation in exon 9 of the MEN

[☆] Please, cite this article as: Altemir Trallero J, et al. Carcinoid tímico en el contexto de un síndrome de neoplasia endocrina múltiple (MEN 1). ¿Timectomía profiláctica? *Endocrinol Nutr.* 2012;59:142-4.